Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 73Myelodysplastic Syndromes 34Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia, Biphenotypic, Acute 17Hematologic Neoplasms 14Burkitt Lymphoma 14Myeloproliferative Disorders 13Leukemia, Myelomonocytic, Chronic 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 7Myelodysplastic-Myeloproliferative Diseases 6Multiple Myeloma 6Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Primary Myelofibrosis 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Prostatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Hairy Cell 3GATA2 Deficiency 3

Interventions

cabozantinib 1Specimen Handling 1Platinum Compounds 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Crohn Disease × Specimen Handling × Other hematologic neoplasm × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡